Levomilnacipran and vortioxetine： Review of new pharmacotherapies for major depressive disorder

Mei T Liu; Megan E Maroney; Evelyn R Hermes-DeSantis

首页> 中文期刊> 《世界药理学杂志》 >Levomilnacipran and vortioxetine： Review of new pharmacotherapies for major depressive disorder

Levomilnacipran and vortioxetine： Review of new pharmacotherapies for major depressive disorder

开具论文收录证明 >>

期刊封面封底目录下载 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

cqvip:Major depressive disorder(MDD) is a common psychiatric disorder with an estimated lifetime prevalence rate in the range of 13% to 16% in the United States population. Patients with MDD often have symptoms such as depressed mood, loss of interest or pleasure in usual activities, changes in eating or sleeping patterns, fatigue, difficulty concentrating and thoughts of suicide. Although many pharmacotherapy treatment options are available for MDD, antidepressants can oftencause adverse effects that could affect adherence to the medication. Additionally, it is estimated that MDD is unremitting in 15% of patients and 35% can have recurrent episodes. Given the high rate of recurrence and the adverse effects associated with existing medications, new treatment options for depression are needed. Both levomilnacipran and vortioxetine are new antidepressants that were approved by the food and drug administration in 2013 for the treatment of MDD in adults. Levomilnacipran is a serotonin norepinephrine reuptake inhibitor that was effective in several short term studies and sustained efficacy and tolerability was demonstrated in a 48-wk extension study. Vortioxetine is a multi-modal antidepressant and it is thought to work via inhibition of the serotonin(5-HT) transporter, 5-HT3 A, 5-HT7 and 5-HT1 D antagonist, a 5-HT1 B partial agonist, and a 5-HT1 A agonist. Vortioxetine was effective in the treatment of MDD in both short-term trials as well as in the prevention of relapse in a 24-36 wk trial. Sustained efficacy and tolerability was demonstrated in several long-term open-label trials. Further studies comparing levomilnacipran and vortioxetine to other currently available antidepressants are needed to establish its place in therapy.

著录项

来源
《世界药理学杂志》 |2015年第1期|P.17-30|共14页
作者
Mei T Liu; Megan E Maroney; Evelyn R Hermes-DeSantis;
展开▼
作者单位

Pharmacy Practice and Administration;

Ernest Mario School of Pharmacy;

Rutgers;

the State University of New Jersey;

Piscataway;

NJ 08854;

United States;

Pharmacy Practice and Administration;

Ernest Mario School of Pharmacy;

Rutgers;

the State University of New Jersey;

Piscataway;

NJ 08854;

United States;

Pharmacy Practice and Administration;

Ernest Mario School of Pharmacy;

Rutgers;

the State University of New Jersey;

Piscataway;

NJ 08854;

United States;

展开▼
原文格式 PDF
正文语种 CHI
中图分类 R749.410.6;
关键词
重度抑郁症; 治疗方法; 临床分析; 抗抑郁剂;

相似文献

中文文献
外文文献
专利

Levomilnacipran and vortioxetine： Review of new pharmacotherapies for major depressive disorder

摘要

著录项

相似文献

相关主题

期刊订阅